Sanofi and Regeneron Pharmaceuticals Inc. recently presented Phase 3 clinical trial data and multiple additional analyses from the Praluent (alirocumab) Injection's Odyssey clinical trial program at the American College of Cardiology Scientific Sessions in Washington, D.C.
The Praluent study examined the effects of the drug on several patient subsets such as diabetes, heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease. The study also included post-hoc analyses looking at the effect of Praluent on major cardiovascular events.
Sanofi noted in its news release that praluent is a human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). The drug is approved in close to 40 countries worldwide, including the United States, Japan, Canada, Switzerland, Mexico, Brazil and the European Union.
Sanofi is a global health care company that focuses on therapeutic solutions helping patients lead healthier lives. It has five business units – Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial.
Regeneron, a science-based biopharmaceutical company, develops medicines for serious medical conditions, including eye diseases, high LDL-cholesterol, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer and infectious diseases.